Idiopathic MF is very rarely diagnosed in children and should be differentiated from acute megakaryocytic leukemia; metastatic neoplasms; and connective tissue, metabolic, and bone diseases. It is characterized by BM fibrosis, megakaryocytes with bizarre morphology, splenomegaly, anemia, and extramedullary hematopoiesis. Idiopathic MF is a clonal disorder, with approximately half of adult patients having mutations in JAK2 V617F. Recent studies have suggested that angiogenic cytokines produced by megakaryocytes and monocytes and their receptors (platelet-derived growth factor receptors, vascular endothelial growth factor receptor-2, and fibro blast growth factor receptor) may be involved in the pathogenesis of the myelofibrosis.
Treatment algorithms for adult MF have been proposed (Fig. 1). Numerous treatment approaches have been attempted with variable degrees of success. These include splenectomy, splenic radiation, transfusions, androgens, corticosteroids, hydroxyurea, and IFN-α. More recently, based on preliminary studies about the potential role of angiogenic cytokines and their receptors, newer approaches have been tested, including the tyrosine kinase inhibitor imatinib and the antiangiogenic agent thalidomide. Selective JAK inhibitors have been successfully used in patients with IM with a dramatic improvement in the quality of life, but without generalized reduction of the JAK2 V617F burden allele. In 2011, the United States Food and Drug Administration granted approval to the first of these agents, ruxolitinib, for adults with IM. However, the safety and efficacy of ruxolitinib in children is still unknown. Further trials are investigating the combination of JAK inhibition in combi nation with other therapeutic modalities, such as PI3K inhibition, mammalian target of rapamycin inhibition, histone deacetylase inhibition, and antifibrotic agents.

Fig1. TREATMENT ALGORITHM FOR ADULT MYELOFIBROSIS. aDirectly to hematopoietic cell transplantation or after bridging therapy to decrease marrow blasts. (From Jain T, Mesa RA, Palmer JM. Allogeneic stem cell transplantation in myelofibrosis. Biol Blood Marrow Transplant. 2017;23(9):1429–1436.)
Retrospective adult studies suggest that MF patients who respond to JAK2 inhibitors have significantly improved post-HCT OS, though a prospective trial was complicated by signs of ruxolitinib withdrawal, including cardiogenic shock and tumor lysis. When used, it appears important to continue JAK2 inhibition until close to the start time of conditioning chemotherapy.
Allogeneic HCT is the only potentially curative option for MF, with resolution of BM fibrosis in donor-engrafted patients, but high rates of transplant-related complications, even with reduced intensity conditioning. Risk-prediction models (assessing age, performance status, WBC and platelet parameters, mutation status, and donor type) have been built for adults undergoing HCT for MF, which identifies groups with 5-year survival rates as low as 22% and as high as 83%, though whether this data is applicable to children is unknown. Algorithms to help determine whether adult patients should undergo HCT have been proposed (Fig. 2).

Fig2. SELECTION OF UPFRONT THERAPY FOR PATIENTS WITH MYELOFIBROSIS: HEMATOPOIETIC CELL TRANSPLANTATION (HCT) VERSUS NONTRANSPLANT THERAPIES. (Adapted from Devlin R, Gupta V. Myelofibrosis: to transplant or not to transplant? Hematology. 2016;2016[1]:543–551.)